HCM - HUTCHMED (China) Ltd

QQQ $ 435.24 $ 2.91 (0.67 %)

DIA $ 386.71 $ 0.03 (0.01 %)

SPY $ 511.01 $ 0.48 (0.09 %)

TLT $ 89.60 $ -0.51 (-0.57 %)

GLD $ 212.66 $ -0.76 (-0.36 %)

Previous Close

$ 19.56

Open

$ 19.18

Bid

$ 19.15 x 100

Ask

$ 19.26 x 100

Day's Range

$ 19.02 - $ 19.24

52 Week Range

$ 10.68 - $ 20.73

Volume

120,034

Average Volume

Market Cap

3.41B

Beta (5Y Monthly)

$ 1.20

PE Ratio (TTM)

$ 33.82

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HUTCHMED Announces Positive CHMP Opinion F...
04/26/2024 12:36:52

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer reg...

HUTCHMED Says Initial Preclinical Data For...
04/05/2024 09:18:47

Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the ...

HUTCHMED And Innovent Announce NDA Accepta...
04/02/2024 05:43:46

— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July...

On Wednesday, HUTCHMED Announced Savolitin...
03/28/2024 08:55:06

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Applic...

Reported Earlier, HUTCHMED Initiated Regis...
03/22/2024 07:16:46

hello-group-posts-q4-results-joins-sentinelone-futu-holdings-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

Hello Group Posts Q4 Results, Joins Sentin...
03/14/2024 09:52:31

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.

why-clover-health-investments-shares-are-trading-higher-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Clover Health Investments Shares Are T...
03/13/2024 17:18:56

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
03/13/2024 13:06:03

Why SurgePays Shares Are Trading Lower By ...
03/13/2024 12:24:11

Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-exp...

beauty-health-posts-upbeat-sales-joins-siga-technologies-maxcyte-and-other-big-stocks-moving-higher-in-wednesdays-pre-market-session

Beauty Health Posts Upbeat Sales, Joins SI...
03/13/2024 10:16:13

U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.

HUTCHMED Sees FY24 Oncology/Immunology Rev...
02/28/2024 12:13:29

Full year 2024 guidance for Oncology/Immunology consolidated revenue is $300 million to $400 million, driven by 30% to 50% grow...

HUTCHMED (China) FY EPS $0.58 Up From $(2....
02/28/2024 11:32:35

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.58 per share. This is a 127.23 percent increase over losses of ...

Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

Airbnb Reports Q4 Results, Joins MGM Resor...
02/14/2024 09:55:56

U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 80 points on Wednesday.

HUTCHMED Presented Phase III Data On Fruqu...
02/07/2024 05:36:07

Fruquintinib demonstrated a statistically significant improvement in multiple other endpoints, including disease control rate (...

HUTCHMED Announces that Inmagene Exercises...
02/02/2024 08:35:29

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals (&#...

HUTCHMED Receives ELUNATE Marketing Approv...
01/30/2024 07:20:15

First medicine approved under new "1+" mechanism by HKSAR Government, providing an important treatment option to pati...

HUTCHMED's New Drug Application For Sovlep...
01/11/2024 06:33:57

NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 NDA is suppo...

HUTCHMED Confirms ELUNATE® And SULANDA® Re...
12/13/2023 06:44:08

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED...

Reported Earlier, HUTCHMED Completes Enrol...
12/13/2023 06:42:26

The first patient in China received the first dose on October 27, 2022 and HUTCHMED expects to announce topline results from th...